ATE:CC News and Press, Antibe Therapeutics Inc. From 11/13/23

- Completed successful PK/PD study for otenaproxesul’s new formulation - Phase II initiation on track for upcoming quarter - Ended quarter with $28 million in cash and equivalents Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology compan...

Fission Uranium Corp. (FCU:CA) is expected to report for Q1 2024 Power Corporation of Canada Subordinate Voting Shares (POW:CA) is expected to report $1 for Q3 2023 Spark Power Group Inc. (SPG:CA) is expected to report for Q1 2024 ECN Capital Corp. (ECN:CA) is expected to report $0.02...

Antibe Therapeutics Inc. (ATE:CA) is expected to report $-0.12 for Q2 2024

- Study delivers data required for Phase II trial, on track to initiate next quarter - Confirms linear, dose-proportional pharmacokinetics - Complements strong safety data already reported Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biot...

- All treatments well tolerated with no adverse safety signals - No elevations in liver enzymes Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting...

- Data in November will inform Phase II trial expected to launch next quarter Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announ...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic (ȁ...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier tod...

2023-09-02 20:00:00 ET Antibe Therapeutics is now ranked among the top 10 undervalued stocks in the Biotechnology industry on the Toronto Stock Exchange or TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used...

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite Canada NewsWire TORONTO , Aug. 21, 2023 /CNW/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview ...